Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Altimmune to Present at Upcoming Investor and Scientific Conferences

February 4, 2020 GMT

GAITHERSBURG, Md., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following conferences during the months of February:

2020 BIO CEO & Investor Conference Date: Monday, February 10 Time: 10:45am ET Title: Altimmune, Inc. Overview Speaker: Vipin K. Garg Ph. D., President and Chief Executive Officer Location: New York Marriott Marquis, New York, NY Webcast: https://ir.altimmune.com/investors/events-and-presentations The 3rdGlobal NASH Conference Date: Tuesday, February 11 Time: 11:55 am GMT / 6:55 am ET Title: Dual GLP-1 Agonists in the Treatment of Metabolic & Liver Dysfunction in NASH Speaker: M. Scott Harris M.D., Chief Medical Officer Location: The London Heathrow Marriott Hotel, London, UK Presentation: https://ir.altimmune.com/investors/events-and-presentations

About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver diseases and immune modulating therapies. The Company’s diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoShield™ and NasoVAX™). For more information on Altimmune, please visit www.altimmune.com.

Contacts Will Brown Ashley R. Robinson Chief Financial Officer Managing Director LifeSci Advisors Phone: 240-654-1450 Phone: 617-535-7742 Email: wbrown@altimmune.com Email: arr@lifesciadvisors.com